Safety of antiandrogen therapy for treating prostate cancer

Bibliography

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29
   PubMed Web of Science ®Google Scholar
• Albertsen PC, Moore DF, Shih W, et al. Impact of comorbidity on survival among men with localized prostate cancer. J ClinOncol 2011;29(10):1335-41
   PubMed Web of Science ®Google Scholar
• Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94(13):981-90
   PubMed Web of Science ®Google Scholar
• Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 2009;101(18):1280-3
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004;22:2141-9
   PubMed Web of Science ®Google Scholar
• Roach M III, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26(4):585-91
   PubMed Web of Science ®Google Scholar
• Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21(21):3972-8
   PubMed Web of Science ®Google Scholar
• Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61(5):1285-90
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472-9
   PubMed Web of Science ®Google Scholar
• Li J, Djenaba JA, Soman A, et al. Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer 2012;2012:691380
   PubMedGoogle Scholar
• Lepor H, Shore ND. Luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer: 2012. Rev Urol 2012;14(1-2):1-12
   PubMedGoogle Scholar
• Lam JS, Leppert JT, Vemulapalli SN, et al. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006;175(1):27-34
   PubMed Web of Science ®Google Scholar
• Van Poppel H, Klotz L. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol 2012;19(7):594-601
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65(2):467-79
   PubMed Web of Science ®Google Scholar
• Klotz L, Miller K, Crawford ED, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol 2014, pii: S0302-2838(13)01491-7
   Web of Science ®Google Scholar
• Helsen C, Kerkhofs S, Clinckemalie L, et al. Structural basis for nuclear hormone receptor DNA binding. Mol Cell Endocrinol 2012;348(2):411-17
   PubMed Web of Science ®Google Scholar
• Denayer S, Helsen C, Thorrez L, et al. The rules of DNA recognition by the androgen receptor. Mol Endocrinol 2010;24(5):898-913
   PubMed Web of Science ®Google Scholar
• Gioeli DG. The promise of novel androgen receptor antagonists. Cell Cycle 2010;9(3):440-1
   PubMed Web of Science ®Google Scholar
• Gillatt D. Antiandrogen treatments in locally advanced prostate cancer: are they all the same? J Cancer Res Clin Oncol 2006;132(Suppl 1):S17-26
   PubMedGoogle Scholar
• Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54
   PubMed Web of Science ®Google Scholar
• Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67(10):5033-41
   PubMed Web of Science ®Google Scholar
• Schmitt B, Bennett C, Seidenfeld J, et al. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2000;2:CD001526
   PubMedGoogle Scholar
• Schmitt B, Wilt TJ, Schellhammer PF, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001;57(4):727-32
   PubMed Web of Science ®Google Scholar
• Moul JW. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. Cancer 2009;115:3376-8
   PubMed Web of Science ®Google Scholar
• Verhelst J, Denis L, Van Vliet P, et al. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) 1994;41(4):525-30
   PubMed Web of Science ®Google Scholar
• Wadhwa VK, Weston R, Parr NJ. Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer. BJU Int 2011;107(12):1923-9
   PubMed Web of Science ®Google Scholar
• Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 1.2014. J Natl Compr Canc Netw 2013;11(12):1471-9
   PubMed Web of Science ®Google Scholar
• Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566-77
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999;17(7):2027-38
   PubMed Web of Science ®Google Scholar
• Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000;164(5):1579-82
   PubMed Web of Science ®Google Scholar
• Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of ’Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33(5):447-56
   PubMed Web of Science ®Google Scholar
• Rathkopf D, Scher HI. Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J 2013;19(1):43-9
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Morris MJ, Fox JJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol 2013;31(28):3525-30
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, A’Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27(23):3742-8
   PubMed Web of Science ®Google Scholar
• O’Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90(12):2317-25
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-48
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, Auchus RJ, et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012;97(2):507-16
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424-33
   PubMed Web of Science ®Google Scholar
• Tombal B, Borre M, Rathenborg P, et al. Enzalutamide monotherpy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol 2014;15(6):592-600
   PubMed Web of Science ®Google Scholar
• Kunath F, Keck B, Antes G, et al. Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review. BMC Med 2012;10:96
   PubMed Web of Science ®Google Scholar
• Chatelain C, Fourcade RO, Delchambre J. Bicalutamide (CasodexTM) versus combined androgen blockade (CAB): open French multicentre study in patients with metastatic prostate cancer [abstract 1111]. Br J Urol 1997;80(Suppl 2):283
   Google Scholar
• Iversen P, McLeod DG, See WA, et al. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int 2010;105(8):1074-81
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005;23:808-15
   PubMed Web of Science ®Google Scholar
• Saltzstein D, Sieber P, Morris T, Gallo J. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis 2005;8(1):75-83
   PubMed Web of Science ®Google Scholar
• Bedognetti D, Rubagotti A, Conti G, et al. An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. Eur Urol 2010;57(2):238-45
   PubMed Web of Science ®Google Scholar
• Kaisary AV. Antiandrogen monotherapy in the management of advanced prostate cancer. Eur Urol 1997;31(Suppl 2):14-19
   PubMedGoogle Scholar
• Decensi AU, Boccardo F, Guarneri D, et al. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol 1991;146:377-81
   PubMed Web of Science ®Google Scholar
• Petit JH, Gluck C, Kiger WS III, et al. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity. Urol Oncol 2008;26(4):372-7
   PubMed Web of Science ®Google Scholar
• Boccon-Gibod L, Fournier G, Bottet P, et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 1997;32(4):391-5
   PubMed Web of Science ®Google Scholar
• Schröder FH, Whelan P, de Reijke TM, et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. Eur Urol 2004;45(4):457-64
   PubMed Web of Science ®Google Scholar
• Wirth MP, Weissbach L, Marx FJ, et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004;45(3):267-70
   PubMed Web of Science ®Google Scholar
• Langenstroer P, Porter HJ II, McLeod DG, Thrasher JB. Direct gastrointestinal toxicity of flutamide: comparison of irradiated and non-irradiated cases. J Urol 2004;171(2 Pt 1):684-6
   PubMed Web of Science ®Google Scholar
• Yagoda A. Flutamide-induced diarrhea secondary to lactose intolerance. J Natl Cancer Inst 1989;81:1839
   PubMed Web of Science ®Google Scholar
• Boccardo F, Pace M, Rubagotti A, et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. Eur J Cancer 1993;29A(8):1088-93
   PubMed Web of Science ®Google Scholar
• Iversen P. Zoladex plus flutamide vs orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA). Eur Urol 1990;18(Suppl 3):41-4
   PubMedGoogle Scholar
• Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998;33(2):144-51
   PubMed Web of Science ®Google Scholar
• Fau D, Eugene D, Berson A, et al. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 1994;269(3):954-62
   PubMed Web of Science ®Google Scholar
• Iwanaga T, Nakakariya M, Yabuuchi H, et al. Involvement of bile salt export pump in flutamide-induced cholestatic hepatitis. Biol Pharm Bull 2007;30(4):739-44
   PubMed Web of Science ®Google Scholar
• Thole Z, Manso G, Salgueiro E, et al. Hepatotoxicity induced by antiandrogens: a review of the literature. Urol Int 2004;73(4):289-95
   PubMed Web of Science ®Google Scholar
• Boccardo F, Decensi AU, Guarneri D, et al. Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study. Cancer Detect Prev 1991;15(6):501-3
   PubMedGoogle Scholar
• Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol 1997;158(1):160-3
   PubMed Web of Science ®Google Scholar
• Béland G, Elhilali M, Fradet Y, et al. Total androgen ablation: canadian experience. Urol Clin North Am 1991;18:75-82
   PubMed Web of Science ®Google Scholar
• Harris MG, Coleman SG, Faulds D, Chrisp P. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 1993;3(1):9-25
   PubMed Web of Science ®Google Scholar
• Tyrrell CJ, Iversen P, Tammela T, et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU Int 2006;98(3):563-72
   PubMed Web of Science ®Google Scholar
• Kaisary AV, Iversen P, Tyrrell CJ, et al. Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prostate Cancer Prostatic Dis 2001;4(4):196-203
   PubMed Web of Science ®Google Scholar
• Dawson LA, Chow E, Morton G. Fulminant hepatic failure associated with bicalutamide. Urology 1997;49:283-4
   PubMed Web of Science ®Google Scholar
• Masago T, Watanabe T, Nemoto R, Motoda K. Interstitial pneumonitis induced by bicalutamide given for prostate cancer. Int J Clin Oncol 2011;16(6):763-5
   PubMed Web of Science ®Google Scholar
• Cockshott ID. Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet 2004;43(13):855-78
   PubMed Web of Science ®Google Scholar
• Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. Eur Urol 2007;51(2):306-13
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375(9724):1437-46
   PubMed Web of Science ®Google Scholar
• Foster WR, Car BD, Shi H, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 2011;71:480-8
   PubMed Web of Science ®Google Scholar
• Sternberg CN, de Bono JS, Chi KN, et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol 2014;25(2):429-34
   PubMed Web of Science ®Google Scholar
• Badrising S, van der Noort V, van Oort IM, et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 2014;120(7):968-75
   PubMed Web of Science ®Google Scholar
• Schrader AJ, Boegemann M, Ohlmann CH, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014;65(1):30-6
   PubMed Web of Science ®Google Scholar
• Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012;72(6):1494-503
   PubMed Web of Science ®Google Scholar
• Mazzola CR, Mulhall JP. Impact of androgen deprivation therapy on sexual function. Asian J Androl 2012;14:198-203
   PubMed Web of Science ®Google Scholar
• Wibowo E, Wassersug RJ. The effect of estrogen on the sexual interest of castrated males: implications to prostate cancer patients on androgen-deprivation therapy. Crit Rev Oncol Hematol 2013;87(3):224-38
   PubMed Web of Science ®Google Scholar
• Iversen P. Quality of life issues relating to endocrine treatment options. Eur Urol 1999;36(Suppl 2):20-6
   PubMed Web of Science ®Google Scholar
• Frisk J. Managing hot flushes in men after prostate cancer: a systematic review. Maturitas 2010;65(1):15-22
   PubMed Web of Science ®Google Scholar
• Fonseca RS, Rajkumar V, White WL, et al. Anemia after orchiectomy. Am J Hematol 1998;59:230-3
   PubMed Web of Science ®Google Scholar
• Curtis KK, Adam TJ, Chen SC, et al. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review. Aging Male 2008;11(4):157-61
   PubMed Web of Science ®Google Scholar
• Frye CA, Edinger KL. Testosterone’s metabolism in the hippocampus may mediate its anti-anxiety effects in male rats. Pharmacol Biochem Behav 2004;78:473-81
   PubMed Web of Science ®Google Scholar
• Green HJ, Pakenham KI, Headley BC, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 2002;90(4):427-32
   PubMed Web of Science ®Google Scholar
• Green HJ, Pakenham KI, Headley BC, et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int 2004;93(7):975-9
   PubMed Web of Science ®Google Scholar
• Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol 2008;5(1):24-34
   PubMedGoogle Scholar
• Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res 2002;57:385-409
   PubMedGoogle Scholar
• Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 2009;104(6):800-5
   PubMed Web of Science ®Google Scholar
• Allan G, Lai MT, Sbriscia T, et al. A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats. J Steroid Biochem Mol Biol 2007;103(1):76-83
   PubMed Web of Science ®Google Scholar
• Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24(27):4448-56
   PubMed Web of Science ®Google Scholar
• Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005;63(3):280-93
   PubMed Web of Science ®Google Scholar
• Muller M, Grobbee DE, den Tonkelaar I, et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005;5):2618-23
   PubMed Web of Science ®Google Scholar
• Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006;24(24):3979-83
   PubMed Web of Science ®Google Scholar
• Derweesh IH, Diblasio CJ, Kincade MC, et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 2007;100(5):1060-5
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011;306(21):2359-66
   PubMed Web of Science ®Google Scholar
• Barry MJ, Delorenzo MA, Walker-Corkery ES, et al. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int 2006;98(5):973-8
   PubMed Web of Science ®Google Scholar
• Dockery F, Bulpitt CJ, Agarwal S, et al. Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer. Clin Endocrinol (Oxf) 2008;68(1):59-6
   PubMed Web of Science ®Google Scholar
• Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102(1):39-46
   PubMed Web of Science ®Google Scholar